drugset
drugset / Trial / NCT06978738

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

NCT06978738 ↗

Phase 1 Not yet recruiting 18 enrolled Changzhou No.2 People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.

Timeline

Start
2025-05
Primary completion
2027-05
Completion
2028-11

Drugs

EvaluationDrugModalityDoseRoute
Subject universal allogeneic anti-CD19/BCMA CAR T-cells Cell therapy — Intravenous

Indications

anti-neutrophil cytoplasmic antibody-associated vasculitis autoimmune hemolytic anemia immunoglobulin G4-related sclerosing disease myasthenia gravis myositis disease systemic lupus erythematosus systemic sclerosis